our mission patients vary in more ways than gender, race, and size. at conformis, we believe that optimizing implant fit and performance requires a patient-specific approach. our mission is to provide best-in-class, patient-specific implants and instrumentation that offer unique advantages over traditional orthopedic implants. we start with a simple idea: make the implant fit the patient rather than forcing the patient to fit the implant. our implants are individually sized and shaped to fit to each patient’s unique anatomy, providing precise anatomic fit and preserving healthy tissue. our disposable, patient-specific cutting and placement guides also eliminate many of the tools required for traditional orthopedic surgery and simplify surgical technique. by combining our personalized implants with our unique instrumentation, a surgeon is able to provide a custom solution that preserves more of a patient’s joint and minimizes surgical trauma. our company conformis, inc. is a privately h
Company profile
Ticker
CFMS
Exchange
Website
CEO
Mark A. Augusti
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Zimmer Biomet • Enovis • Steris • Intuitive Surgical • Edwards Lifesciences • Avanos Medical • MSA Safety • INVACARE • Align Technology • Surgalign ...
SEC CIK
Corporate docs
Subsidiaries
Conformis Cares LLC • ConforMIS Europe GmbH • ConforMIS Hong Kong Limited • ConforMIS UK Limited • ImaTX, Inc. ...
CFMS stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
15 Sep 23
25-NSE
Exchange delisting
5 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Sep 23
Transcripts
CFMS
Earnings call transcript
2023 Q1
8 May 23
CFMS
Earnings call transcript
2022 Q4
1 Mar 23
CFMS
Earnings call transcript
2022 Q3
3 Nov 22
CFMS
Earnings call transcript
2022 Q2
9 Aug 22
CFMS
Earnings call transcript
2022 Q1
4 May 22
CFMS
Earnings call transcript
2021 Q4
2 Mar 22
CFMS
Earnings call transcript
2021 Q3
4 Nov 21
CFMS
Earnings call transcript
2021 Q2
5 Aug 21
CFMS
Earnings call transcript
2021 Q1
9 May 21
CFMS
Earnings call transcript
2020 Q4
4 Mar 21
Latest ownership filings
4
Christine Desrochers
5 Sep 23
4
Mark A Augusti
5 Sep 23
4
CARRIE BIENKOWSKI
5 Sep 23
4
Gary P Fischetti
5 Sep 23
4
Denise E Pedulla
5 Sep 23
4
Bradley Langdale
5 Sep 23
4
PHILIP W JOHNSTON
5 Sep 23
4
KENNETH P FALLON III
5 Sep 23
SC 13G/A
WASATCH ADVISORS LP
10 Jul 23
3
Christine Desrochers
21 Jun 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.64 mm | 26.64 mm | 26.64 mm | 26.64 mm | 26.64 mm | 26.64 mm |
Cash burn (monthly) | 3.87 mm | 3.87 mm | 4.33 mm | 3.71 mm | 3.76 mm | 3.71 mm |
Cash used (since last report) | 38.33 mm | 38.36 mm | 42.87 mm | 36.78 mm | 37.29 mm | 36.77 mm |
Cash remaining | -11.68 mm | -11.72 mm | -16.23 mm | -10.14 mm | -10.65 mm | -10.12 mm |
Runway (months of cash) | -3.0 | -3.0 | -3.8 | -2.7 | -2.8 | -2.7 |
Institutional ownership, Q2 2023
64.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 32 |
Opened positions | 4 |
Closed positions | 5 |
Increased positions | 6 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 1.15 bn |
Total shares | 5.08 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tasik Temenggor Investments | 2.39 mm | $3.58 mm |
aeris CAPITAL Archer | 1.89 mm | $5.10 mm |
Renaissance Technologies | 175.30 k | $384.00 k |
UBS UBS Group AG - Registered Shares | 120.91 k | $264.80 mm |
BLK Blackrock | 120.44 k | $263.75 mm |
Vanguard | 107.47 k | $235.36 mm |
Skandinaviska Enskilda Banken AB | 100.00 k | $219.00 k |
Geode Capital Management | 66.93 k | $146.57 mm |
STA Wealth Management | 34.19 k | $74.87 mm |
STT State Street | 24.67 k | $54.02 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Sep 23 | Christine Desrochers | Common Stock | Sale back to company | Dispose D | No | No | 0 | 81,465 | 0.00 | 0 |
5 Sep 23 | Augusti Mark A | Common Stock | Sale back to company | Dispose D | No | No | 0 | 190,277 | 0.00 | 0 |
5 Sep 23 | Augusti Mark A | Common Stock | Grant | Acquire A | No | No | 0 | 17,778 | 0.00 | 190,277 |
5 Sep 23 | Gary P Fishetti | Common Stock | Sale back to company | Dispose D | No | No | 0 | 10,470 | 0.00 | 0 |
5 Sep 23 | Bienkowski Carrie | Common Stock | Sale back to company | Dispose D | No | No | 0 | 19,909 | 0.00 | 0 |
5 Sep 23 | Denise E Pedulla | Common Stock | Sale back to company | Dispose D | No | No | 0 | 18,000 | 0.00 | 0 |